HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Shares Doubts About Supplements, Ad Claims In Its Consumer Library

This article was originally published in The Rose Sheet

Executive Summary

FTC announces an addition to its library of consumer information with on supplements. It also notes online initiative by the Consortium for Health and Military Performance at the Uniformed Services University of the Health Sciences "mostly intended for the military community" but also relevant to other consumers.

You may also be interested in...



Durbin’s DoD Supplement Proposal Could Be ‘Back Door’ To Pre-market Approval Rule

The Illinois senator proposes an amendment to the National Defense Authorization Act that would require third-party verification for supplements sold at any commissary or other retail store operating on a DoD installation.

Military Report Slams DMAA While GNC Claims Victory

A Department of Defense safety review panel does not find a conclusive causal association between DMAA and adverse events, including four service members’ deaths, a conclusion that “delighted” retailer GNC. But DoD’s ban on sales of DMAA products in military exchanges and concessions remains in place.

Final Guidance For Reporting Adverse Events Gets Serious On Definitions

A report of emergency room treatment connected to use of a dietary supplement may not connote a serious adverse event, FDA says in the final guidance on the reporting and recordkeeping of AE information for supplements

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel